GCA
UTHR icon

Greenwood Capital Associates’s United Therapeutics UTHR Stock Holding History

Greenwood Capital Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,185
Closed -$577K – 310
2025
Q4 		$577K Sell
1,185
-203
-15% -$94.5K 0.06% 172
2025
Q3 		$582K Sell
1,388
-822
-37% -$276K 0.07% 174
2025
Q2 		$635K Sell
2,210
-139
-6% -$41.5K 0.08% 162
2025
Q1 		$724K Buy
+2,349
New +$805K 0.1% 152
2016
Q1 		– Sell
-1,389
Closed -$218K – 177
2015
Q4 		$218K Buy
+1,389
New +$202K 0.07% 147
2015
Q3 		– Sell
-1,814
Closed -$315K – 194
2015
Q2 		$315K Buy
1,814
+285
+19% +$51.3K 0.1% 110
2015
Q1 		$263K Buy
+1,529
New +$233K 0.08% 128

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Greenwood Capital Associates's UTHR Position: Q1 2026 in Review

Greenwood Capital Associates sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 1,185 shares — an estimated $577K sold.

Greenwood Capital Associates first reported a position in UTHR in Q1 2015 and held it in 7 quarters. The position peaked at $724K in Q1 2025. 853 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Greenwood Capital Associates reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Greenwood Capital Associates sold 1,185 United Therapeutics shares in Q1 2026, an estimated $577K.
  • Greenwood Capital Associates first reported a position in United Therapeutics in Q1 2015 and held it in 7 quarters.
  • Greenwood Capital Associates's United Therapeutics position peaked at $724K in Q1 2025.
  • 853 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Greenwood Capital Associates's 13F filing for Q1 2026, filed 29 Apr 2026.